CT
CRSP icon

Colonial Trust’s CRISPR Therapeutics CRSP Stock Holding History

Colonial Trust’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.16K Buy
58
+30
+107% +$1.58K ﹤0.01% 968
2026
Q1 		$1.33K Buy
+28
New +$1.48K ﹤0.01% 1049
2025
Q1 		– Sell
-36
Closed -$1.42K – 1160
2024
Q4 		$1.42K Hold
36
– – ﹤0.01% 1240
2024
Q3 		$1.69K Hold
36
– – ﹤0.01% 1017
2024
Q2 		$1.94K Hold
36
– – ﹤0.01% 939
2024
Q1 		$2.45K Hold
36
– – ﹤0.01% 913
2023
Q4 		$2.25K Buy
36
+11
+44% +$608 ﹤0.01% 891
2023
Q3 		$1.14K Hold
25
– – ﹤0.01% 927
2023
Q2 		$1.4K Hold
25
– – ﹤0.01% 913
2023
Q1 		$1.13K Hold
25
– – ﹤0.01% 877
2022
Q4 		$1.02K Buy
+25
New +$1.33K ﹤0.01% 879

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Colonial Trust's CRSP Position: Q2 2026 in Review

Colonial Trust increased its CRISPR Therapeutics (CRSP) stake by 107% in Q2 2026, buying an estimated $1.58K and bringing the position to 58 shares worth $3.16K. The position accounts for ﹤0.01% of the portfolio, ranked #968.

Colonial Trust first reported a position in CRSP in Q4 2022 and has held it in 11 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Colonial Trust held 58 shares of CRISPR Therapeutics worth $3.16K as of Q2 2026.
  • Colonial Trust bought 30 CRISPR Therapeutics shares in Q2 2026, an estimated $1.58K.
  • CRISPR Therapeutics made up ﹤0.01% of Colonial Trust's portfolio in Q2 2026, its #968 holding.
  • Colonial Trust first reported a position in CRISPR Therapeutics in Q4 2022 and has held it in 11 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Colonial Trust's 13F filing for Q2 2026, filed 11 Aug 2026.